ATARA BIOTHERAPEUTICS, INC.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $167.5M | $81.2M | $56.5M | $41.6M | $15.4M | — |
| SG&A Expense | $69.7M | $40.3M | $24.7M | $16.8M | $12.7M | $3.8M |
| Operating Income | $-237.1M | $-121.5M | $-81.2M | $-58.4M | $-28.2M | $-8.6M |
| Operating Margin | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | $-230.7M | $-119.5M | $-79.0M | $-57.2M | $-28.0M | $-8.6M |
| Income Tax Expense | $-44.0K | $-14.0K | $10.0K | $-9.0K | $-25.0K | $170.0K |
| Net Income | $-230.7M | $-119.5M | $-79.0M | $-57.2M | $-28.0M | $-8.8M |
| Net Margin | — | — | — | — | — | — |
| EPS (Basic) | $-5.27 | $-4.00 | $-2.75 | — | — | — |
| EPS (Diluted) | $-5.27 | $-4.00 | $-2.75 | — | — | — |
| Shares Outstanding (Basic) | 46.0M | 30.7M | 28.9M | 28.5M | 19.7M | 12.0M |
| Shares Outstanding (Diluted) | 46.0M | 30.7M | 28.9M | 28.5M | 19.7M | 12.0M |
| Dividends Per Share | — | — | — | — | — | — |